news

Demand for ‘specialist skills’ in UK cell and gene therapy, says report

5
SHARES

A skills demand report has stated that employment in the UK cell and gene therapy industry is expected to double by 2024, but must be supported by targeted academic courses.

DNA strand with highlighted gene region

A report released by the Cell and Gene Therapy Catapult (CGT Catapult) states that employment in the UK cell and gene therapy industry is set to double by 2024. This increase, according to the report, must be supported by targeted programmes that provide the necessary skilled staff.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The UK cell and gene therapy skills demand report highlighted that jobs in this industry had expanded from 500 in 2012 to over 3,000 in 2019, and predicted it would grow to more than 6,000 by 2024. The report particularly highlighted the growth of the manufacturing and bioprocessing sector, which currently has 1,700 roles – triple that of two years ago.

The report suggests that the growing Advanced Therapy Medicinal Product (ATMP) ecosystem and the increasing number of clinical trials being run in the UK are drivers of this growth. In particular, the CGT Catapult cite the expanding pipeline of ATMPs in approved for use and in clinical trials, as promoting the demand for specialised personnel.

However, the report indicates there are concerns over how demand will be met; primarily, the availability of targeted academic courses.

The CGT Catapult concluded that initiatives such as the Advanced Therapies Apprenticeship Community (ATAC) would be important to prevent shortages of skilled workers going forward.

The ATAC, was the first apprenticeship scheme set up in collaboration with the Medicines Manufacturing Industry Partnership, designed to train and upskill people in ATMPs. The programme was awarded £1.5m funding by the Industrial Strategy Challenge Fund, has developed five courses and currently supports 21 companies.

Share via
Share via